SUBSCRIBE
SUBSCRIBE

Search Results

129 Results
Type
Section
Tag
Date
129 Results for "archerdx".
  • Job Trends
    ArcherDX to Present at Cowen’s 2020 Liquid Biopsy Summit
    ArcherDX, Inc. today announced that Jason Myers, Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at Cowen’s 2020 Liquid Biopsy Summit at 2:00 p.m. Eastern Daylight Time (EDT) / 12:00 p.m. Mountain Daylight Time (MDT).
    September 17, 2020
     · 
    3 min read
  • ArcherDX to Participate in UBS Genomics 2.0 and Medtech Innovations Virtual Summit
    ArcherDX, Inc. today announced that Jason Myers , Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Virtual Summit.
    August 5, 2020
     · 
    3 min read
  • ArcherDX to Participate in Morgan Stanley 18th Annual Global Healthcare Conference
    ArcherDX, Inc. today announced that Jason Myers , Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the Morgan Stanley 18 th Annual Global Healthcare Conference at 3:45 p.m. Eastern Daylight Time (EDT) / 1:45 p.m. Mountain Daylight Time (MDT).
    September 8, 2020
     · 
    3 min read
  • Policy
    Natera Files Additional Suit Against ArcherDX
    Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera’s U.S. Patent No. 10,731,220 (the “‘220 Patent”). The complaint was filed in the U.S. District Court of Delaware .
    August 7, 2020
     · 
    2 min read
  • Business
    ArcherDX Appoints Jason Ryan to Board of Directors
    ArcherDX, Inc. today announced the appointment of Jason Ryan , Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company’s Board of Directors and as the Chair of the Audit Committee.
    May 7, 2020
     · 
    4 min read
  • BioMidwest
    ArcherDX and UCL Extend TRACERx Program Collaboration to Evaluate Cancer Evolution
    ArcherDX, Inc., UCL and the Francis Crick Institute announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK.
    August 3, 2020
     · 
    7 min read
  • Policy
    Natera Asserts Three New Oncology Patents Against ArcherDX
    Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today asserted three recently issued oncology patents against ArcherDX in its ongoing patent infringement action filed in the U.S. District Court of Delaware.
    April 15, 2020
     · 
    3 min read
  • Policy
    ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
    ArcherDX, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its next-generation sequencing device under development as a companion diagnostic to detect neurotrophic receptor tyrosine kinase gene fusions that lead to the formation and growth of cancer.
    May 19, 2020
     · 
    4 min read
  • Business
    ArcherDX Appoints Mark Massaro Chief Financial Officer
    ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance and enable the practice of personalized genomic medicine, today announced Mark Massaro has been appointed Chief Financial Officer.
    January 7, 2020
     · 
    2 min read
  • Policy
    Natera Files Suit Against ArcherDX for Patent Infringement
    Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera’s U.S. Patent No. 10,538,814 (the “‘814 patent”).
    January 27, 2020
     · 
    3 min read